Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

October 9, 2023

Study Completion Date

October 9, 2023

Conditions
Breast CancerChronic Pain Due to Malignancy (Finding)
Interventions
DRUG

Sulfasalazine

This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.

DRUG

Placebos

This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.

Trial Locations (2)

85713

Banner University Medical Center South, Tucson

85719

Banner University Medical Center North Campus, Tucson

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER